News | November 06, 2012

Is Declining Medical Imaging Use Driving Up Hospital Stays and Medical Costs?

New report highlights possible downside to cost cutting for medical imaging scans

Imaging Clinical Study CT Systems Medical Stays Medical Cost

November 6, 2012 — A new report by the Harvey L. Neiman Health Policy Institute shows that the length of the average hospital stay in the United States has increased at the same time as use of medical imaging scans has declined. It is unclear if the trends are related, but potentially important, as hospital admissions are among the largest, and fastest growing, healthcare costs. More research is needed to assess the potential negative impact of government and private insurer imaging reductions on overall medical costs and patient safety.

“Lawmakers, regulators and medical professionals are making medical imaging policy decisions without fully understanding or examining their downstream effects — which may include an increase in hospital stays, associated costs and other adverse events. We need to examine imaging, as it relates to a patient’s overall continuum of care, to ensure that decision makers don’t create imaging cost reduction policies which paradoxically raise overall costs, create barriers to care, and ultimately harm patients,” said Richard Duszak, M.D., chief executive officer and senior research fellow of the Harvey L. Neiman Health Policy Institute.

Much of a building body of research regarding medical imaging focuses on declining costs and utilization of imaging. There is relatively little research focused on imaging as a component of overall patient care. For many serious indications, imaging scans have been shown to reduce the number of invasive surgeries, unnecessary hospital admissions and length of hospital stays. Rarer still is data on the effect of $6 billion in funding reductions for imaging diagnosis and treatment planning since 2006. The information that is available is not necessarily positive in terms of patient safety and access to care.

This is the first policy brief produced by the Neiman Institute, which conducts and supports research regarding medical imaging use, quality and safety metrics, and human resources as medicine moves toward non-traditional, value-based payment and delivery. The data gleaned from these efforts will serve as the basis for true, evidence-based medical imaging policy.

“We need to take a hard look at the cost, access and quality and safety issues related to present government and private insurer medical imaging policies and find ways to maximize the value, role and efficiency of radiology as healthcare systems evolve. The Neiman Institute will provide much needed information to ensure that future imaging policies benefit patients and make efficient, effective use of healthcare resources,” said Duszak.                                                                                                                     

For more information: neimanhpi.org


Related Content

News | Cardiovascular Clinical Studies

Nov. 18, 2024 — Silence Therapeutics presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a ...

Home November 18, 2024
Home
News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
News | Cardiovascular Clinical Studies

July 10, 2024 — CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and ...

Home July 10, 2024
Home
News | Cardiovascular Clinical Studies

July 9, 2024 — Microbot Medical Inc. announced the completion of the first procedure in a patient utilizing its LIBERTY ...

Home July 09, 2024
Home
News | Cardiovascular Clinical Studies

June 26, 2024 — Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves ...

Home June 26, 2024
Home
News | Cardiovascular Clinical Studies

June 21, 2024 — Lexicon Pharmaceuticals, Inc. announced that the peer-reviewed Journal of the American College of ...

Home June 21, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — Microbot Medical Inc. announced its agreement with Brigham and Women’s Hospital (BWH), a leading ...

Home June 20, 2024
Home
Subscribe Now